Curasight Feed

	Tid*
2025-02-20	07:00	Bokslutskommuniké 2024
2024-11-21	-	Kvartalsrapport 2024-Q3
2024-08-22	-	Kvartalsrapport 2024-Q2
2024-07-02	-	Extra Bolagsstämma 2024
2024-05-23	-	Kvartalsrapport 2024-Q1
2024-03-22	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2024-03-21	-	Årsstämma
2024-02-22	-	Bokslutskommuniké 2023
2023-11-23	-	Kvartalsrapport 2023-Q3
2023-08-24	-	Kvartalsrapport 2023-Q2
2023-05-25	-	Kvartalsrapport 2023-Q1
2023-03-31	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2023-03-30	-	Årsstämma
2023-02-23	-	Bokslutskommuniké 2022
2022-11-24	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-24	-	Kvartalsrapport 2022-Q1
2022-04-27	-	Årsstämma
2022-03-25	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2022-02-24	-	Bokslutskommuniké 2021
2021-11-25	-	Kvartalsrapport 2021-Q3
2021-08-24	-	Kvartalsrapport 2021-Q2
2021-06-01	-	Extra Bolagsstämma 2021
2021-05-20	-	Kvartalsrapport 2021-Q1
2021-03-26	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2021-03-25	-	Årsstämma
2021-02-24	-	Bokslutskommuniké 2020
2020-11-30	-	Kvartalsrapport 2020-Q3

Land	Danmark
Lista	Spotlight DK
Sektor	Hälsovård
Industri	Medicinteknik

2024-12-10 19:05:17 Participation in warrant exercise by Curasight management 11,00 DKK | +7,84% | 0,09 MDKK

2024-12-10 07:22:00 Curasight A/S announces outcome of warrant exercise 10,20 DKK | -6,85% | 0,42 MDKK

2024-12-02 08:10:00 Curasight: SEB maintain valuation range midpoint at DKK 54 per share 11,30 DKK | +1,35% | 0,45 MDKK

2024-12-02 07:00:00 Curasight: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 11,30 DKK | +1,35% | 0,45 MDKK

2024-11-22 08:25:06 Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] 10,90 DKK | -5,22% | 0,04 MDKK

2024-11-21 07:55:00 Curasight: The exercise period for warrants of series TO2 commences today 11,50 DKK | -3,36% | 0,10 MDKK

2024-11-21 07:00:00 Curasight: Interim report Q3 2024 11,50 DKK | -3,36% | 0,10 MDKK

2024-11-20 08:10:00 Curasight: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share 11,90 DKK | -6,30% | 0,11 MDKK

2024-11-14 07:00:00 Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference 11,50 DKK | -0,43% | 0,18 MDKK

2024-11-13 07:05:00 Curasight announces international patent application for uTREAT® to broaden IP protection 11,55 DKK | -1,28% | 0,02 MDKK

2024-11-11 07:00:00 Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 11,05 DKK | +5,74% | 0,08 MDKK

2024-11-08 10:42:58 Curasight to present at Dansk Aktionærforening InvestorDagen 10,45 DKK | -0,95% | 0,03 MDKK

2024-11-07 07:00:00 Curasight: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer 10,55 DKK | -4,52% | 0,04 MDKK

2024-10-11 13:19:10 Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3 11,00 DKK | 0,00% | 0,01 MDKK

2024-10-03 08:41:29 Curasight A/S rights issue heavily oversubscribed 11,00 DKK | +3,29% | 0,15 MDKK

2024-09-16 08:50:00 Commencement of subscription period in Curasight's preferential rights issue 9,68 DKK | -3,68% | 0,06 MDKK

2024-09-12 12:22:24 Curasight A/S publishes prospectus due to upcoming rights issue 10,00 DKK | -6,10% | 0,24 MDKK

2024-09-04 09:25:00 Curasight: The Board of Directors resolves on a directed issue of units and preferential rights issue of units 11,00 DKK | -6,38% | 0,04 MDKK

2024-08-22 07:00:00 Curasight: Interim report Q2 2024 11,90 DKK | -0,42% | 0,00 MDKK

2024-07-30 10:39:16 Curasight issues warrants as part of long-term incentive program 11,20 DKK | +3,70% | 0,02 MDKK

2024-07-02 14:11:38 Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024 12,00 DKK | -2,04% | 0,06 MDKK

2024-07-01 11:53:10 Curasight: Directed issues registered at the Danish Business Authority 12,25 DKK | -2,00% | 0,13 MDKK

2024-06-22 11:22:54 Curasight to present at HC Andersen Capital

2024-06-17 16:05:55 Curasight: Notice of Extraordinary General Meeting 13,75 DKK | -14,06% | 0,20 MDKK

2024-06-14 17:22:12 Curasight A/S resolves on directed issues and a loan facility 16,00 DKK | +6,67% | 0,38 MDKK

2024-06-12 07:11:00 Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer 13,00 DKK | +19,82% | 0,25 MDKK

2024-05-23 07:00:00 Curasight: Interim report Q1 2024 10,30 DKK | 0,00% | 0,00 MDKK

2024-04-16 20:39:38 Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients 10,15 DKK | -1,93% | 0,10 MDKK

2024-04-12 11:58:04 Curasight announces change in the Board of Directors 10,00 DKK | +3,09% | 0,07 MDKK

2024-03-21 12:30:31 Resolutions of the Annual General Meeting 2024 of Curasight A/S 10,90 DKK | -6,03% | 0,13 MDKK

2024-03-11 21:53:10 Curasight not to proceed with rights issue; evaluating alternative financing opportunities 10,65 DKK | -28,28%

2024-03-06 11:26:47 Curasight: Notice of Annual General Meeting 2024 15,20 DKK | +2,36%

2024-02-23 08:35:35 The subscription period in Curasight's rights issue begins today 16,00 DKK | -1,23% | 0,59 MDKK

2024-02-22 12:47:45 Curasight publishes information memorandum in connection with forthcoming rights issue 16,20 DKK | +1,25% | 0,17 MDKK

2024-02-22 08:46:13 Curasight: Annual Report for the fiscal year 2023 16,20 DKK | +1,25% | 0,17 MDKK

2024-02-22 07:00:00 Curasight: Year-end report October - December 2023 16,20 DKK | +1,25% | 0,17 MDKK

2024-02-13 08:13:40 Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy 16,50 DKK | -8,33% | 0,39 MDKK

2024-02-13 08:11:14 Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company 16,50 DKK | -8,33% | 0,39 MDKK

2024-01-22 07:00:00 Curasight A/S Achieves First Milestone under collaboration with Curium Inc. 18,90 DKK | +0,80% | 0,20 MDKK

2023-12-18 18:31:25 Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients 17,00 DKK | -2,86% | 0,36 MDKK

2023-12-13 17:53:30 Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer 18,25 DKK | +4,89% | 0,21 MDKK

2023-11-24 07:00:00 Curasight to present at HC Andersen Capital and Stokk.io 17,95 DKK | -2,45% | 0,04 MDKK

2023-11-23 07:00:00 Curasight: Interim Report January - September 2023 18,40 DKK | +2,22% | 0,04 MDKK

2023-10-18 07:20:00 Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC) 18,00 DKK | -1,10% | 0,14 MDKK

2023-09-14 17:20:00 Curasight: Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague 19,45 DKK | -2,02% | 0,06 MDKK

2023-08-25 12:26:39 Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar 18,50 DKK | -1,07% | 0,24 MDKK

2023-08-24 07:22:18 Curasight: Interim Report January - June 2023 18,70 DKK | -1,06% | 0,08 MDKK

2023-06-29 08:53:01 Curasight: Positive results in uPAR-PET/MR Phase II study in brain cancer 24,20 DKK | 0,00% | 0,63 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Curasight

Kalender

Beskrivning

Curasight

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden